Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon)

Human Reproduction

Volumn 14, Issue 12, 1999, Pages 2969-2973

  Buckler, H M ^a   Robertson, W R ^b   Anderson, A ^a   Vickers, M ^a   Lambert, A ^b  

^a HOPE HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Ovulation induction; Puregon ; Recombinant FSH

Indexed keywords

ESTRADIOL; INHIBIN A; RECOMBINANT FOLLITROPIN;

ADULT; ANOVULATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL PRACTICE; FEMALE; FEMALE INFERTILITY; HUMAN; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE;

EID: 0032742006     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.12.2969     Document Type: Article

References (34)

1. Adams, J., Polson, D.W. and Franks, S. (1986) Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J., 293, 355-359.
2. Anobile, C.J., Talbot, J.A., McCann, S.J. et al. (1998) Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol. Hum. Reprod., 4, 631-639.
3. Brown, J.B. (1987) Pituitary control of ovarian function - concepts derived from gonadotropin therapy. Aust. N.Z. Obstet. Gynaecol., 18, 47-55.
4. Buckler, H.M., Lambert, A., Anderson, A. et al. (1998a) Low dose alternate day recombinant FSH in an ovulation induction programme. Hum. Reprod., 13 (Abstract Bk. 1), P-138.
5. Buckler, H.M., Lambert, A., Anderson, A. et al. (1998b) Ovulation induction with low dose alternate day recombinant FSH (Puregon). IFFS '98 Program Supplement. Fertil. Steril., Abs P-1129, S-475.
6. ChristinMaitre, S., Taylor, A.E., Khoury, R.H. et al. (1996) Homologous in-vitro bioassay for follicle-stimulating-hormone (FSH) reveals increased FSH biological signal during the mid-phase to late luteal-phase of the human menstrual-cycle. J. Clin. Endocrinol. Metab., 81, 2080-2088.
7. Coelingh Bennink, H.J.T., Fauser, B.C.J.M. and Out, H.J. (1998) Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotrophic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. Fertil. Steril., 69, 19-25.
8. Conway, G.S., Honour, J.W., Jacobs H.S. (1989) Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol., 30, 459-470.
9. Devroey, P., Tournaye, H., Van Steirteghem, A. et al. (1998) The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum. Reprod., 13, 565-566.
10. Ding, Y. and Huhtaniemi, I. (1991) Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with the high bio/immuno ratio of LH in healthy women and in women with polycystic ovarian disease. Hum. Reprod., 6, 346-350.
11. Fauser, B.C.J.M. and Van Heusden, A.M. (1997) Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr. Rev., 18, 71-106.
12. Franks, S. (1989) Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol., 31, 187-220.
13. Groome, N.P., Illingworth, P.J., O'Brien, M. et al. (1996) Measurement of dimeric inhibin-B throughout the normal menstrual cycle. J. Clin. Endocrinol Metab., 81, 1400-1405.
14. Harris, S.D., Anobile, C.J., McLoughlin, J. et al. (1996) Internal carbohydrate complexity of the oligosaccharide chains of recombjnant human follicle stimulating hormone (Puregon, ORG 32489); comparison with Metrodin and Metrodin HP. Molec. Hum. Reprod., 2, 807-811.
15. Hayden, C.J., Rutherford, A.J. and Balen, A. (1999) Induction of ovulation with a starting dose of 50 units of recombinant human follicle-stimulating hormone (Puregon). Fertil. Steril., 71, 106-108.
16. Horsman, G., Talbot, J.A., McLoughlin, J.D. et al. (1998) A biological, immunological, and physico-chemical comparison of Gonal-F and Puregon. Hum. Reprod., 13 (Abstract Bk. 1), O-100.
17. Lambert, A., Rodgers, M., Mitchell, R. et al. (1995). In-vitro biopotency and glycoform distribution of recombinant human FSH (ORG32489), Metrodin and Metrodin-HP. Hum. Reprod., 10, 1928-1935.
18. Lockwood, G.M., Muttukrishna, S., Groome, N.P. et al. (1996) Circulating inhibins and activin-A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer. Clin. Endocrinol., 45, 741-748.
19. Lockwood, G.M., Muttukrishna, S., Groome, N.P. et al. (1998) Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J. Clin. Endocrinol. Metab., 83, 1730-1735.
20. Mannaerts, B.M.J.L., Rombout, F., Out, H.J. et al. (1996) Clinical profiling of recombinant follicle stimulating hormone: (rFSH; Puregon): relationship between serum FSH and efficacy. Hum. Reprod. Update, 2, 153-161.
21. Muttukrishna, S., Fowler, P.A., George, L. et al. (1996) Changes in peripheral serum concentrations of total activin-A during the human menstrual cycle and pregnancy. J. Clin. Endocrinol Metab., 81, 3328-3334.
22. Out, H.J., Mannaerts, B.M., Driessen, S.G. et al. (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod., 10, 2534-2540.
23. Pache, T.D., Hop, W.C., De Yong, F.H. et al. (1992) 17 beta-oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. Clin. Endocrinol., 36, 565-571.
24. Recombinant Human FSH Study Group (1995) Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril, 63, 77-86.
25. Recombinant Human FSH Study Group (1998) A compilation of previously published papers. Fertil. Steril., 69 (Suppl.1), 1S-44S.
26. Rodgers, M., Mitchell, R., Lambert A. et al. (1992) Human chorionic gonadotrophin contributes to the bioactivity of Pergonal. Clin. Endocrinol., 37, 558-564.
27. Rodgers, M., McLoughlin, J.D., Lambert, A. et al. (1995) Variability in the immunoreactive and bioactive follicle stimulating hormone content of human urinary menopausal gonadotrophin preparations. Hum. Reprod., 10, 1982-1986.
28. School, D.C., Coelingh Bennink, H.J.T., Mannaerts, B.M.J.L. et al. (1992) Human recombinant follicle stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and oestrogen biosynthesis in a woman with isolated gonadotrophin deficiency. J. Clin. Endocrinol. Metab., 74, 1471-1473.
29. Shoham, Z., Mannaerts, B., Insler, V. et al. (1993) Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotrophic hypogonadism. Fertil. Steril., 59, 738-742.
30. Taylor, A.E., McCourt, B., Martin, K.A. et al. (1997) Determinants of abnormal gonadotrophin secretion in clinically defined women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 2248-2256.
31. Thompson, K.A., LaPolt, P.S., River, J. et al. (1995) Gonadotrophin requirements of the developing follicle. Fertil. Steril., 63, 273-276.
32. Van der Meer, M., Hompes, P.G.A., Scheele, F. et al. (1994) Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome. Hum. Reprod., 9, 1612-1617.
33. White, D.M., Polson, D.W., Kiddy, D. et al. (1996) Extensive personal experience: induction of ovulation with low-dose gonadotrophins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab., 81, 3821-3824.
34. World Health Organization (1973) Agents stimulating gonadal function in the human. Report of a WHO specific group. World Health Org. Techn. Rep. Ser., 514, 1-28.